Insider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $45,276.48 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 1,194 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total value of $45,276.48. Following the completion of the sale, the executive vice president now directly owns 33,713 shares of the company’s stock, valued at $1,278,396.96. The trade was a 3.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Eric Swayze also recently made the following trade(s):

• On Wednesday, October 16th, Eric Swayze sold 53 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $38.31, for a total value of $2,030.43.

Ionis Pharmaceuticals Price Performance

IONS stock opened at $34.34 on Friday. The firm has a 50 day moving average of $39.62 and a 200-day moving average of $42.76. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86. Ionis Pharmaceuticals, Inc. has a 12-month low of $34.24 and a 12-month high of $54.44.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on IONS shares. The Goldman Sachs Group raised their target price on shares of Ionis Pharmaceuticals from $33.00 to $37.00 and gave the stock a “sell” rating in a research report on Friday, August 2nd. Barclays increased their target price on shares of Ionis Pharmaceuticals from $45.00 to $51.00 and gave the stock an “equal weight” rating in a research note on Friday, August 2nd. Piper Sandler decreased their price objective on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a research report on Thursday. Guggenheim cut their price target on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, October 9th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Ionis Pharmaceuticals from $50.00 to $55.00 and gave the company a “neutral” rating in a research report on Monday, August 26th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.65.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Teachers Retirement System of The State of Kentucky increased its position in shares of Ionis Pharmaceuticals by 70.6% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 24,083 shares of the company’s stock valued at $1,044,000 after buying an additional 9,965 shares in the last quarter. Entropy Technologies LP purchased a new position in Ionis Pharmaceuticals during the 1st quarter valued at about $630,000. Edgestream Partners L.P. purchased a new position in Ionis Pharmaceuticals during the 1st quarter valued at about $765,000. Blair William & Co. IL raised its position in Ionis Pharmaceuticals by 67.4% during the first quarter. Blair William & Co. IL now owns 27,838 shares of the company’s stock worth $1,207,000 after acquiring an additional 11,210 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Ionis Pharmaceuticals in the first quarter valued at about $613,000. 93.86% of the stock is owned by institutional investors and hedge funds.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.